A Phase 3 interventional study of Rotigotine 1 mg/24 h and Rotigotine 2 mg/24 h in Restless Legs Syndrome, sponsored by UCB Biopharma SRL. Terminated at 1 site in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-10-30.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing rotigotine in Restless Legs Syndrome — none open to participants now, none under way, none of them phase 3. rotigotine · Restless Legs Syndrome.
Among the 19 studies testing rotigotine in Restless Legs Syndrome, this one is the 19th largest by enrollment, is the only one that started in 2019, is one of 10 in phase 3, and was the 19th registered.
259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.
Browse Restless Legs Syndrome studies →None of the 19 studies testing rotigotine in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.
This study: 13 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2019.
This study's enrollment of 10 is below the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.
Median enrollment 130 across the 19 interventional studies. Of the 19 that completed or were terminated, 13 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 19 have an industry lead sponsor. The 7 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
17 studies in Restless Legs Syndrome by UCB S.A.: none open now, none under way, none of them phase 3. Of 17 finished, 11 (65%) have results posted.
Among the 17 studies in Restless Legs Syndrome by UCB S.A., this one is the 15th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2019, is one of 9 in phase 3, and was the 17th registered.
UCB S.A.’s Restless Legs Syndrome studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing rotigotine in Restless Legs Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 17 in Restless Legs Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the long-term safety, tolerability and the long-term efficacy of rotigotine treatment in adolescents with idiopathic Restless Legs Syndrome (RLS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be initiated on 1 mg/24 h rotigotine and up-titrated to a maximum of 3 mg/24 h rotigotine, with the aim of achieving the individually optimized dosage. Dose adjustment of rotigotine is allowed at any time during the following Maintenance Period up to a maximum dose of 3 mg/24 h. At the end of the Maintenance Period, subjects will be down-titrated.
Drug: Rotigotine 1 mg/24 h · Drug: Rotigotine 2 mg/24 h · Drug: Rotigotine 3 mg/24 h
Drug page: Rotigotine
Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 mg/24 h (5 cm\^2 patch size).
Also known as: Neupro
Drug page: Rotigotine
Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 mg/24 h (10 cm\^2 patch size).
Also known as: Neupro
Drug page: Rotigotine
Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 3 mg/24 h (15 cm\^2 patch size).
Also known as: Neupro
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. TEAEs were defined as events that started during the Treatment Period or within 30 days following the end of the Treatment Period (ie, on or after the date of first patch application and within 30 days following the date of last patch removal + 1 day), or those events where the intensity worsened within this time frame.
Time frame: From Baseline until the Safety Follow-Up Visit (up to 14 Months)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal of Study Medication
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. TEAEs were defined as events that started during the Treatment Period or within 30 days following the end of the Treatment Period (ie, on or after the date of first patch application and within 30 days following the date of last patch removal + 1 day), or those events where the intensity worsened within this time frame.
Time frame: From Baseline until the Safety Follow-Up Visit (up to 14 Months)
Changes From Baseline in International Restless Legs Rating Scale (IRLS) Sum Score at Visit 9
The IRLS consisted of 10 questions, each scored using a 5-point scale ranging from 0=not present to 4=very severe. The IRLS sum score was calculated by summing up the single scores of all applicable questions, i.e., the total sum score ranged from 0 (no RLS symptoms present) to 40 (maximum severity in all symptoms). A score between 31 and 40, indicates very severe RLS. A score between 21 and 30 indicates severe RLS. A score between 11 and 20 indicates moderate RLS. A score between 1 and 10 indicates mild RLS and a score of 0 means no RLS. A negative change from Baseline indicates improvement.
Time frame: Visit 9 (Month 12), compared to Baseline (in SP1006)
Changes From Baseline in Clinical Global Impressions (CGI) Item 1 at Visit 9
The Clinical Global Impressions Item 1 (Severity of Illness) score ranges from 0 to 7 as follows: 0=not assessed, 1=normal, not ill at all, 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill. The CGI Item 1 was completed during an interview between the participant and the investigator or designee. A negative change from Baseline indicates improvement.
Time frame: Visit 9 (Month 12), compared to Baseline (in SP1006)
Changes From Baseline in Restless Legs-6 Rating Scales (RLS-6) at Visit 9
The RLS-6 Rating Scales was designed to assess the severity of RLS and consisted of 6 subscales. The subscales assessed severity of symptoms at the following times of the day/evening: falling asleep, during the night, during the day at rest, and during the day when engaged in daytime activities (not at rest). In addition, the subscales assessed satisfaction with sleep and severity of daytime tiredness/sleepiness. Scores for each of the 6 subscales ranged from 0 (completely satisfied) to 10 (completely dissatisfied). The change from baseline was derived for each of the subscales and reported in this outcome measure. A negative change from Baseline indicates improvement.
Time frame: Visit 9 (Month 12), compared to Baseline (in SP1006)
The study started to enroll participants in December 2019 and concluded prematurely in September 2022. Study participants entered this study from the parent rotigotine study in adolescents (SP1006) (NCT03728933).
| Milestone | No Treatment | Rotigotine Final Dose 2 mg/24 h | Rotigotine Final Dose 3 mg/24 h |
|---|---|---|---|
| Started | 1 | 2 | 7 |
| Completed | 0 | 2 | 7 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Lost to follow-up prior dosing | 1 | 0 | 0 |
| Milestone | No Treatment | Rotigotine Final Dose 2 mg/24 h | Rotigotine Final Dose 3 mg/24 h |
|---|---|---|---|
| Started | 0 | 2 | 7 |
| Completed | 0 | 2 | 1 |
| Not completed | 0 | 0 | 6 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Poor drug compliance withdrawn by team and sponsor | 0 | 0 | 1 |
| Withdrew: Withdrawal due to non-compliance | 0 | 0 | 1 |
| Withdrew: Pi's decision due to investigational medicinal product non-compliance | 0 | 0 | 1 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 2 |
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. TEAEs were defined as events that started during the Treatment Period or within 30 days following the end of the Treatment Period (ie, on or after the date of first patch application and within 30 days following the date of last patch removal + 1 day), or those events where the intensity worsened within this time frame.
| percentage of participants | Rotigotine Final Dose 2 mg/24 h | Rotigotine Final Dose 3 mg/24 h |
|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | 100 | 85.7 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. TEAEs were defined as events that started during the Treatment Period or within 30 days following the end of the Treatment Period (ie, on or after the date of first patch application and within 30 days following the date of last patch removal + 1 day), or those events where the intensity worsened within this time frame.
| percentage of participants | Rotigotine Final Dose 2 mg/24 h | Rotigotine Final Dose 3 mg/24 h |
|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal of Study Medication | 0 | 0 |
The IRLS consisted of 10 questions, each scored using a 5-point scale ranging from 0=not present to 4=very severe. The IRLS sum score was calculated by summing up the single scores of all applicable questions, i.e., the total sum score ranged from 0 (no RLS symptoms present) to 40 (maximum severity in all symptoms). A score between 31 and 40, indicates very severe RLS. A score between 21 and 30 indicates severe RLS. A score between 11 and 20 indicates moderate RLS. A score between 1 and 10 indicates mild RLS and a score of 0 means no RLS. A negative change from Baseline indicates improvement.
| score on a scale | Rotigotine Final Dose 2 mg/24 h | Rotigotine Final Dose 3 mg/24 h |
|---|---|---|
| Changes From Baseline in International Restless Legs Rating Scale (IRLS) Sum Score at Visit 9 | NA ± NA | NA ± NA |
The Clinical Global Impressions Item 1 (Severity of Illness) score ranges from 0 to 7 as follows: 0=not assessed, 1=normal, not ill at all, 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill. The CGI Item 1 was completed during an interview between the participant and the investigator or designee. A negative change from Baseline indicates improvement.
| score on a scale | Rotigotine Final Dose 2 mg/24 h | Rotigotine Final Dose 3 mg/24 h |
|---|---|---|
| Changes From Baseline in Clinical Global Impressions (CGI) Item 1 at Visit 9 | NA ± NA | NA ± NA |
The RLS-6 Rating Scales was designed to assess the severity of RLS and consisted of 6 subscales. The subscales assessed severity of symptoms at the following times of the day/evening: falling asleep, during the night, during the day at rest, and during the day when engaged in daytime activities (not at rest). In addition, the subscales assessed satisfaction with sleep and severity of daytime tiredness/sleepiness. Scores for each of the 6 subscales ranged from 0 (completely satisfied) to 10 (completely dissatisfied). The change from baseline was derived for each of the subscales and reported in this outcome measure. A negative change from Baseline indicates improvement.
| score on a scale | Rotigotine Final Dose 2 mg/24 h | Rotigotine Final Dose 3 mg/24 h |
|---|---|---|
| Satisfaction with sleep | NA ± NA | NA ± NA |
| Severity: RLS symptoms at falling asleep | NA ± NA | NA ± NA |
| Severity: RLS symptoms during the night | NA ± NA | NA ± NA |
| Severity: RLS symptoms during the day - at rest | NA ± NA | NA ± NA |
| Severity: RLS symptoms during the day-not at rest | NA ± NA | NA ± NA |
| How tired or sleepy during the day | NA ± NA | NA ± NA |
Collected over From Baseline until the Safety Follow-Up Visit (up to 14 Months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rotigotine Final Dose 2 mg/24 h | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Rotigotine Final Dose 3 mg/24 h | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| Event | Rotigotine Final Dose 2 mg/24 h | Rotigotine Final Dose 3 mg/24 h |
|---|---|---|
| Application site erythemaGeneral disorders | 2/2 | 2/7 |
| Upper respiratory tract infectionInfections and infestations | 1/2 | 1/7 |
| Suspected COVID-19Infections and infestations | 1/2 | 0/7 |
| Procedural dizzinessInjury, poisoning and procedural complications | 1/2 | 0/7 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 1/2 | 0/7 |
| PruritusSkin and subcutaneous tissue disorders | 1/2 | 1/7 |
| NauseaGastrointestinal disorders | 0/2 | 3/7 |
| Application site rashGeneral disorders | 0/2 | 1/7 |
| HypersensitivityImmune system disorders | 0/2 | 1/7 |
| COVID-19Infections and infestations | 0/2 | 1/7 |
The Safety Set consisted of all participants who had at least one patch (rotigotine) applied. Due to data protection/data privacy, data cannot be reported for a single participant.
| Age, Customized(Participants) | Rotigotine Final Dose 2 mg/24 h | Rotigotine Final Dose 3 mg/24 h | Total |
|---|---|---|---|
| Adolescents (12-17 years) | 2 | 7 | 9 |
| Sex: Female, Male(Participants) | Rotigotine Final Dose 2 mg/24 h | Rotigotine Final Dose 3 mg/24 h | Total |
|---|---|---|---|
| Female | 2 | 2 | 4 |
| Male | 0 | 5 | 5 |
| Race/Ethnicity, Customized(Participants) | Rotigotine Final Dose 2 mg/24 h | Rotigotine Final Dose 3 mg/24 h | Total |
|---|---|---|---|
| Black or African American | 0 | 1 | 1 |
| White | 2 | 6 | 8 |
| Race/Ethnicity, Customized(Participants) | Rotigotine Final Dose 2 mg/24 h | Rotigotine Final Dose 3 mg/24 h | Total |
|---|---|---|---|
| Not Hispanic or Latino | 2 | 7 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if a determination is made that the data cannot be adequately anonymized.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Dec 2019 to primary completion in Sep 2022, 32 months.
Results were first posted in Oct 2023, 1 year 1 month after primary completion. A results delay was requested in Aug 2023.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine